DEALS
Zhong Lun Advises on CMS’ Secondary Listing on SGX
Zhong Lun Advises on CMS’ Secondary Listing on SGX
On July 15, 2025, China Medical System Holdings Limited (“CMS”), a company listed on Hong Kong Stock Exchange (00867.HK), announced its successful secondary listing on the Mainboard of Singapore Exchange Securities Trading Limited by way of introduction (SGX: 8A8).
Zhong Lun Law Firm acted as the PRC legal advisor and provided comprehensive and multi-faceted legal services to CMS in this secondary listing, including but not limited to guiding the client through the application and review process at the Singapore Exchange Securities Trading Limited, administering the internal approval and announcement under the Hong Kong Listing Rules, and handling the filing with China Securities Regulatory Commission. By managing PRC legal matters across these three jurisdictions, Zhong Lun expertly navigated the client through the entire process, garnering recognition and praise from the client and all other stakeholders involved. This project was led by partner Limin Chen. Senior Counsel Hui Yang, partners Liqiong Wang, Zhigang Xu, Xianglong Xu, and non-equity partner Ziwei Li also handled this mandate. Signature lawyers on this project were partner Zhigang Xu, non-equity partner Ziwei Li, and associate Xiaojian Yu. The project team also included associates Xiaohui Li, Jiaman Huang, Yulin Ma, and Qiguang Chen. In addition, partner Jihong Chen, non-equity partner Jian Chen, Jie Lu, and Ruiting Chen provided legal advice on CMS’s data compliance.
Founded in 1995 and listed on the Main Board of the Hong Kong Stock Exchange since 2010, CMS (00867.HK) is a platform company that bridges pharmaceutical innovation and commercialization, boasting strong product lifecycle management capability. With a keen focus on specialty therapeutic fields, such as cardio-cerebrovascular, central nervous system, gastroenterology, dermatology, and ophthalmology, CMS has established a successful academic profile and advantageous market positions for major marketed products. As of December 31, 2024, CMS had deployed approximately forty (40) innovative products with differentiated competitive advantages at various developmental stages, among which, five (5) innovative drugs (covering six (6) indications) have been approved for marketing in China and are entering clinical application. This secondary listing is expected to further enhance CMS’s global visibility, facilitating its international business expansion.
Professionals
-
-
Liqiong WANG
Equity Partner
ShanghaiPractices： Hong Kong & Overseas Capital Markets,Chinese Mainland Capital Markets,Private Equity & Investment FundsIndustries： Real Estate,Transportation & Logistics,Healthcare,Pharmaceuticals & Life Sciences,Education & Training -
Liqiong WANG
Equity Partner
Shanghai
-
